NL-OMON32353尚未招募2 期
Open-label, randomised, multi-center study investigating Cetuximab, in combination with concurrent chemo- / radiotherapy in locally advanced non-small cell lung carcinoma - Cetuximab with concurrent chemo-/radiotherapy in stage II/III NSCLC
Antoni van Leeuwenhoek Ziekenhuis0 个研究点目标入组 112 人开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 112
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Histologically or cytologically confirmed diagnosis of NSCLC
- •2. Stage II/III non-operable disease , without malignant pleural effusion
- •3. Presence of at least one measurable target lesion
- •4. Life expectancy of at least 6 months
- •5. WHO performance 0-1
- •6. Signed written informed consent
排除标准
- •1. Concurrent active malignancy other than localized, non-melanoma skin cancer or carcinoma-in-situ of the cervix (unless definitive treatment was completed 5 years or more before study entry and the patient has remained disease free);
- •a. Ipsilateral radiotherapy to the chest;
- •b. Chemotherapy within the last 5 years;
- •c. Immunotherapy or treatment with murine monoclonal antibodies, Cetuximab, or other EGFR inhibitors.
- •3. WHO performance score > 1
研究者
相似试验
进行中（未招募）
不适用
Open-label, randomised, multi-center study investigating Cetuximab, in combination with concurrent chemo- / radiotherapy in locally advanced non-small cell lung carcinomaEUCTR2007-003894-18-NLKI-AV
进行中（未招募）
1 期
A randomized, open-label, multi-center study comparing a steroid sparing regimen versus standard steroid regimen in combination with daclizumab, mycophenolate mofetil and sirolimus in the prevention of acute renal allograft rejection.Estudio abierto, aleatorizado, multicéntrico, nacional, comparando un régimen libre de esteroides frente a un régimen de esteroides estándar, en combinación con Daclizumab, Micofenolato Mofetil y Sirolimus, en la prevención del rechazo agudo en trasplante renal.Renal TransplantEUCTR2005-003383-39-ESRoche Farma S.A.144
进行中（未招募）
1 期
Multicenter, randomized, open-label study to evaluate the efficacy and safety of SOC + Sarilumab versus Standard of Care for the Early Treatment of COVID-19-pneumonia in Hospitalized PatientsEUCTR2020-002037-15-ESCristina Avendaño Sola200
进行中（未招募）
1 期
A randomized, open-label, multicenter study evaluating thrombovascular events in subjects with cancer receiving chemotherapy and administered epoetin alfa once or three times a week for the treatment of anemia.EUCTR2006-000914-19-GBJanssen-Cilag International N.V.
进行中（未招募）
1 期
A randomized, open-label, multicenter study evaluating thrombovascular events in subjects with cancer receiving chemotherapy and administered epoetin alfa once or three times a week for the treatment of anemia.Anemia in cancer patients receiving chemotherapyMedDRA Version 5.1: list of preferred terma used in the process of defining thrombotic vascular events, see investigator's brochure epoetin alphaEUCTR2006-000914-19-FRJanssen-Cilag International NV, Turnhoutseweg 30, 2340 Beerse, Belgium